Page 10 - திருப்புமுனை சிகிச்சை பதவி News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Search jobs First half of 2021: Boehringer Ingelheim makes fundamental progress in research and development Breakthrough results in the treatment of a type of heart failure, which is extremely difficult to manage Strong progress in mental health pipeline Good business performance in all areas, despite ongoing impact of COVID-19 Ingelheim, August 3, 2021 – In the first half of 2021, Boehringer Ingelheim has supplied more humans and animals worldwide with innovative medicines than ever before. The company’s success is based on its rich R&D portfolio with a focus on diseases with high unmet medical need. The R&D pipeline in Human Pharma comprises more than 60 new substances and around 100 clinical and pre-clinical projects. This pipeline has the potential to deliver up to 15 medicines for approval by 2025.

Rheinland pfalzMichael schmelmerEli lillyQuantum technologyApplication consortiumEuropean commissionBoehringer ingelheimDrug administrationGroup functionsAnimal healthHuman pharmaBreakthrough therapy designationCognitive impairment associatedBiopharmaceutical contract manufacturingManaging directorsLifebit biotech